

COVID-19 Impact on Global Targeted Drug VEGF Inhibitors for NSCLC Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/C9DAEB97608BEN.html>

Date: July 2020

Pages: 92

Price: US\$ 3,900.00 (Single User License)

ID: C9DAEB97608BEN

Abstracts

This report focuses on the global Targeted Drug VEGF Inhibitors for NSCLC status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Targeted Drug VEGF Inhibitors for NSCLC development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America. The key players covered in this study

Roche

Pfizer

Allergan

Amgen

Biocon

Reliance Lifesciences

Beaconpharma

Celgene Corporation

Fujifilm Kyowa Kirin Biologics

Hetero Drugs

Market segment by Type, the product can be split into

Bevacizumab

Other

Market segment by Application, split into

Squamous Cell Carcinoma of NSCLC

Adenocarcinoma of NSCLC

Large Cell Carcinoma of NSCLC

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Targeted Drug VEGF Inhibitors for NSCLC status, future forecast, growth opportunity, key market and key players.

To present the Targeted Drug VEGF Inhibitors for NSCLC development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Targeted Drug VEGF Inhibitors for NSCLC are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Targeted Drug VEGF Inhibitors for NSCLC Revenue

1.4 Market Analysis by Type

1.4.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Bevacizumab

1.4.3 Other

1.5 Market by Application

1.5.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application: 2020 VS 2026

1.5.2 Squamous Cell Carcinoma of NSCLC

1.5.3 Adenocarcinoma of NSCLC

1.5.4 Large Cell Carcinoma of NSCLC

1.6 Coronavirus Disease 2019 (Covid-19): Targeted Drug VEGF Inhibitors for NSCLC Industry Impact

1.6.1 How the Covid-19 is Affecting the Targeted Drug VEGF Inhibitors for NSCLC Industry

1.6.1.1 Targeted Drug VEGF Inhibitors for NSCLC Business Impact Assessment - Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.6.2 Market Trends and Targeted Drug VEGF Inhibitors for NSCLC Potential Opportunities in the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Targeted Drug VEGF Inhibitors for NSCLC Players to Combat Covid-19 Impact

1.7 Study Objectives

1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Targeted Drug VEGF Inhibitors for NSCLC Market Perspective (2015-2026)

2.2 Targeted Drug VEGF Inhibitors for NSCLC Growth Trends by Regions

2.2.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size by Regions: 2015 VS 2020 VS 2026

2.2.2 Targeted Drug VEGF Inhibitors for NSCLC Historic Market Share by Regions (2015-2020)

2.2.3 Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Regions (2021-2026)

2.3 Industry Trends and Growth Strategy

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Challenges

2.3.4 Porter's Five Forces Analysis

2.3.5 Targeted Drug VEGF Inhibitors for NSCLC Market Growth Strategy

2.3.6 Primary Interviews with Key Targeted Drug VEGF Inhibitors for NSCLC Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Targeted Drug VEGF Inhibitors for NSCLC Players by Market Size

3.1.1 Global Top Targeted Drug VEGF Inhibitors for NSCLC Players by Revenue (2015-2020)

3.1.2 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Players (2015-2020)

3.1.3 Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Concentration Ratio

3.2.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by Targeted Drug VEGF Inhibitors for NSCLC Revenue in 2019

3.3 Targeted Drug VEGF Inhibitors for NSCLC Key Players Head office and Area Served

3.4 Key Players Targeted Drug VEGF Inhibitors for NSCLC Product Solution and Service

3.5 Date of Enter into Targeted Drug VEGF Inhibitors for NSCLC Market

3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Targeted Drug VEGF Inhibitors for NSCLC Historic Market Size by Type

(2015-2020)

4.2 Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Type (2021-2026)

5 TARGETED DRUG VEGF INHIBITORS FOR NSCLC BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020)

5.2 Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size (2015-2020)

6.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in North America (2019-2020)

6.3 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020)

6.4 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size (2015-2020)

7.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in Europe (2019-2020)

7.3 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020)

7.4 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020)

8 CHINA

8.1 China Targeted Drug VEGF Inhibitors for NSCLC Market Size (2015-2020)

8.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in China (2019-2020)

8.3 China Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020)

8.4 China Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020)

9 JAPAN

- 9.1 Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size (2015-2020)
- 9.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in Japan (2019-2020)
- 9.3 Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020)
- 9.4 Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

- 10.1 Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size (2015-2020)
- 10.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020)
- 10.4 Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020)

11 INDIA

- 11.1 India Targeted Drug VEGF Inhibitors for NSCLC Market Size (2015-2020)
- 11.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in India (2019-2020)
- 11.3 India Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020)
- 11.4 India Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

- 12.1 Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Size (2015-2020)
- 12.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in Central & South America (2019-2020)
- 12.3 Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020)
- 12.4 Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Roche

13.1.1 Roche Company Details

13.1.2 Roche Business Overview and Its Total Revenue

13.1.3 Roche Targeted Drug VEGF Inhibitors for NSCLC Introduction

13.1.4 Roche Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business
(2015-2020))

13.1.5 Roche Recent Development

13.2 Pfizer

13.2.1 Pfizer Company Details

13.2.2 Pfizer Business Overview and Its Total Revenue

13.2.3 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Introduction

13.2.4 Pfizer Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business
(2015-2020)

13.2.5 Pfizer Recent Development

13.3 Allergan

13.3.1 Allergan Company Details

13.3.2 Allergan Business Overview and Its Total Revenue

13.3.3 Allergan Targeted Drug VEGF Inhibitors for NSCLC Introduction

13.3.4 Allergan Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business
(2015-2020)

13.3.5 Allergan Recent Development

13.4 Amgen

13.4.1 Amgen Company Details

13.4.2 Amgen Business Overview and Its Total Revenue

13.4.3 Amgen Targeted Drug VEGF Inhibitors for NSCLC Introduction

13.4.4 Amgen Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business
(2015-2020)

13.4.5 Amgen Recent Development

13.5 Biocon

13.5.1 Biocon Company Details

13.5.2 Biocon Business Overview and Its Total Revenue

13.5.3 Biocon Targeted Drug VEGF Inhibitors for NSCLC Introduction

13.5.4 Biocon Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business
(2015-2020)

13.5.5 Biocon Recent Development

13.6 Reliance Lifesciences

13.6.1 Reliance Lifesciences Company Details

13.6.2 Reliance Lifesciences Business Overview and Its Total Revenue

- 13.6.3 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Introduction
- 13.6.4 Reliance Lifesciences Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
- 13.6.5 Reliance Lifesciences Recent Development
- 13.7 Beaconpharma
 - 13.7.1 Beaconpharma Company Details
 - 13.7.2 Beaconpharma Business Overview and Its Total Revenue
 - 13.7.3 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Introduction
 - 13.7.4 Beaconpharma Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
 - 13.7.5 Beaconpharma Recent Development
- 13.8 Celgene Corporation
 - 13.8.1 Celgene Corporation Company Details
 - 13.8.2 Celgene Corporation Business Overview and Its Total Revenue
 - 13.8.3 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Introduction
 - 13.8.4 Celgene Corporation Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
 - 13.8.5 Celgene Corporation Recent Development
- 13.9 Fujifilm Kyowa Kirin Biologics
 - 13.9.1 Fujifilm Kyowa Kirin Biologics Company Details
 - 13.9.2 Fujifilm Kyowa Kirin Biologics Business Overview and Its Total Revenue
 - 13.9.3 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Introduction
 - 13.9.4 Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
 - 13.9.5 Fujifilm Kyowa Kirin Biologics Recent Development
- 13.10 Hetero Drugs
 - 13.10.1 Hetero Drugs Company Details
 - 13.10.2 Hetero Drugs Business Overview and Its Total Revenue
 - 13.10.3 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Introduction
 - 13.10.4 Hetero Drugs Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
 - 13.10.5 Hetero Drugs Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Disclaimer

15.3 Author Details

List Of Tables

LIST OF TABLES

- Table 1. Targeted Drug VEGF Inhibitors for NSCLC Key Market Segments
- Table 2. Key Players Covered: Ranking by Targeted Drug VEGF Inhibitors for NSCLC Revenue
- Table 3. Ranking of Global Top Targeted Drug VEGF Inhibitors for NSCLC Manufacturers by Revenue (US\$ Million) in 2019
- Table 4. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026
- Table 5. Key Players of Bevacizumab
- Table 6. Key Players of Other
- Table 7. COVID-19 Impact Global Market: (Four Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast Scenarios)
- Table 8. Opportunities and Trends for Targeted Drug VEGF Inhibitors for NSCLC Players in the COVID-19 Landscape
- Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
- Table 10. Key Regions/Countries Measures against Covid-19 Impact
- Table 11. Proposal for Targeted Drug VEGF Inhibitors for NSCLC Players to Combat Covid-19 Impact
- Table 12. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth by Application (US\$ Million): 2020 VS 2026
- Table 13. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Regions (US\$ Million): 2020 VS 2026
- Table 14. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Regions (2015-2020) (US\$ Million)
- Table 15. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Regions (2015-2020)
- Table 16. Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Regions (2021-2026) (US\$ Million)
- Table 17. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Regions (2021-2026)
- Table 18. Market Top Trends
- Table 19. Key Drivers: Impact Analysis
- Table 20. Key Challenges
- Table 21. Targeted Drug VEGF Inhibitors for NSCLC Market Growth Strategy
- Table 22. Main Points Interviewed from Key Targeted Drug VEGF Inhibitors for NSCLC Players

Table 23. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by Players (2015-2020) (Million US\$)

Table 24. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Players (2015-2020)

Table 25. Global Top Targeted Drug VEGF Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drug VEGF Inhibitors for NSCLC as of 2019)

Table 26. Global Targeted Drug VEGF Inhibitors for NSCLC by Players Market Concentration Ratio (CR5 and HHI)

Table 27. Key Players Headquarters and Area Served

Table 28. Key Players Targeted Drug VEGF Inhibitors for NSCLC Product Solution and Service

Table 29. Date of Enter into Targeted Drug VEGF Inhibitors for NSCLC Market

Table 30. Mergers & Acquisitions, Expansion Plans

Table 31. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 32. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Share by Type (2015-2020)

Table 33. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Type (2021-2026)

Table 34. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Share by Application (2015-2020)

Table 35. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 36. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Share by Application (2021-2026)

Table 37. North America Key Players Targeted Drug VEGF Inhibitors for NSCLC Revenue (2019-2020) (Million US\$)

Table 38. North America Key Players Targeted Drug VEGF Inhibitors for NSCLC Market Share (2019-2020)

Table 39. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 40. North America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2015-2020)

Table 41. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 42. North America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2015-2020)

Table 43. Europe Key Players Targeted Drug VEGF Inhibitors for NSCLC Revenue

(2019-2020) (Million US\$)

Table 44. Europe Key Players Targeted Drug VEGF Inhibitors for NSCLC Market Share (2019-2020)

Table 45. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 46. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2015-2020)

Table 47. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 48. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2015-2020)

Table 49. China Key Players Targeted Drug VEGF Inhibitors for NSCLC Revenue (2019-2020) (Million US\$)

Table 50. China Key Players Targeted Drug VEGF Inhibitors for NSCLC Market Share (2019-2020)

Table 51. China Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 52. China Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2015-2020)

Table 53. China Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 54. China Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2015-2020)

Table 55. Japan Key Players Targeted Drug VEGF Inhibitors for NSCLC Revenue (2019-2020) (Million US\$)

Table 56. Japan Key Players Targeted Drug VEGF Inhibitors for NSCLC Market Share (2019-2020)

Table 57. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 58. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2015-2020)

Table 59. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 60. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2015-2020)

Table 61. Southeast Asia Key Players Targeted Drug VEGF Inhibitors for NSCLC Revenue (2019-2020) (Million US\$)

Table 62. Southeast Asia Key Players Targeted Drug VEGF Inhibitors for NSCLC Market Share (2019-2020)

Table 63. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 64. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2015-2020)

Table 65. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 66. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2015-2020)

Table 67. India Key Players Targeted Drug VEGF Inhibitors for NSCLC Revenue (2019-2020) (Million US\$)

Table 68. India Key Players Targeted Drug VEGF Inhibitors for NSCLC Market Share (2019-2020)

Table 69. India Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 70. India Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2015-2020)

Table 71. India Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 72. India Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2015-2020)

Table 73. Central & South America Key Players Targeted Drug VEGF Inhibitors for NSCLC Revenue (2019-2020) (Million US\$)

Table 74. Central & South America Key Players Targeted Drug VEGF Inhibitors for NSCLC Market Share (2019-2020)

Table 75. Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 76. Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2015-2020)

Table 77. Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 78. Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2015-2020)

Table 79. Roche Company Details

Table 80. Roche Business Overview

Table 81. Roche Product

Table 82. Roche Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US\$)

Table 83. Roche Recent Development

Table 84. Pfizer Company Details

Table 85. Pfizer Business Overview

Table 86. Pfizer Product

Table 87. Pfizer Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US\$)

Table 88. Pfizer Recent Development

Table 89. Allergan Company Details

Table 90. Allergan Business Overview

Table 91. Allergan Product

Table 92. Allergan Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US\$)

Table 93. Allergan Recent Development

Table 94. Amgen Company Details

Table 95. Amgen Business Overview

Table 96. Amgen Product

Table 97. Amgen Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US\$)

Table 98. Amgen Recent Development

Table 99. Biocon Company Details

Table 100. Biocon Business Overview

Table 101. Biocon Product

Table 102. Biocon Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US\$)

Table 103. Biocon Recent Development

Table 104. Reliance Lifesciences Company Details

Table 105. Reliance Lifesciences Business Overview

Table 106. Reliance Lifesciences Product

Table 107. Reliance Lifesciences Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US\$)

Table 108. Reliance Lifesciences Recent Development

Table 109. Beaconpharma Company Details

Table 110. Beaconpharma Business Overview

Table 111. Beaconpharma Product

Table 112. Beaconpharma Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US\$)

Table 113. Beaconpharma Recent Development

Table 114. Celgene Corporation Business Overview

Table 115. Celgene Corporation Product

Table 116. Celgene Corporation Company Details

Table 117. Celgene Corporation Revenue in Targeted Drug VEGF Inhibitors for NSCLC

Business (2015-2020) (Million US\$)

Table 118. Celgene Corporation Recent Development

Table 119. Fujifilm Kyowa Kirin Biologics Company Details

Table 120. Fujifilm Kyowa Kirin Biologics Business Overview

Table 121. Fujifilm Kyowa Kirin Biologics Product

Table 122. Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US\$)

Table 123. Fujifilm Kyowa Kirin Biologics Recent Development

Table 124. Hetero Drugs Company Details

Table 125. Hetero Drugs Business Overview

Table 126. Hetero Drugs Product

Table 127. Hetero Drugs Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US\$)

Table 128. Hetero Drugs Recent Development

Table 129. Research Programs/Design for This Report

Table 130. Key Data Information from Secondary Sources

Table 131. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type: 2020 VS 2026

Figure 2. Bevacizumab Features

Figure 3. Other Features

Figure 4. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application: 2020 VS 2026

Figure 5. Squamous Cell Carcinoma of NSCLC Case Studies

Figure 6. Adenocarcinoma of NSCLC Case Studies

Figure 7. Large Cell Carcinoma of NSCLC Case Studies

Figure 8. Targeted Drug VEGF Inhibitors for NSCLC Report Years Considered

Figure 9. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth 2015-2026 (US\$ Million)

Figure 10. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Regions: 2020 VS 2026

Figure 11. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Regions (2021-2026)

Figure 12. Porter's Five Forces Analysis

Figure 13. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Players in 2019

Figure 14. Global Top Targeted Drug VEGF Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drug VEGF Inhibitors for NSCLC as of 2019)

Figure 15. The Top 10 and 5 Players Market Share by Targeted Drug VEGF Inhibitors for NSCLC Revenue in 2019

Figure 16. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)

Figure 17. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)

Figure 18. China Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)

Figure 19. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)

Figure 20. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)

Figure 21. India Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth

(2015-2020) (Million US\$)

Figure 22. Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)

Figure 23. Roche Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 24. Roche Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)

Figure 25. Pfizer Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 26. Pfizer Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)

Figure 27. Allergan Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 28. Allergan Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)

Figure 29. Amgen Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 30. Amgen Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)

Figure 31. Biocon Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 32. Biocon Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)

Figure 33. Reliance Lifesciences Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 34. Reliance Lifesciences Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)

Figure 35. Beaconpharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 36. Beaconpharma Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)

Figure 37. Celgene Corporation Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 38. Celgene Corporation Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)

Figure 39. Fujifilm Kyowa Kirin Biologics Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 40. Fujifilm Kyowa Kirin Biologics Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)

Figure 41. Hetero Drugs Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 42. Hetero Drugs Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)

Figure 43. Bottom-up and Top-down Approaches for This Report

Figure 44. Data Triangulation

Figure 45. Key Executives Interviewed

I would like to order

Product name: COVID-19 Impact on Global Targeted Drug VEGF Inhibitors for NSCLC Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/C9DAEB97608BEN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C9DAEB97608BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

